Neuroscience specialist Lundbeck has agreed to buy Longboard Pharmaceuticals for $2.6 billion, expanding its pipeline with an epilepsy drug tipped as a future blockbuster.
Takeda’s experimental epilepsy drug soticlestat has failed not one but two phase 3 trials – in Dravet syndrome and Lennox-Gastaut syndrome – throwing the future of the programme in doubt.